Published in final edited form as:

Mol Neurobiol. 2012 February ; 45(1): 109–118. doi:10.1007/s12035-011-8223-z.

Kalirin Signaling: Implications for Synaptic Pathology

Peter Penzes and

Department of Physiology, Northwestern University Feinberg School of Medicine, 303 E. Chicago Avenue, Chicago, IL 60611, USA; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, 303 E. Chicago Avenue, Chicago, IL 60611, USA

Christine Remmers

Department of Physiology, Northwestern University Feinberg School of Medicine, 303 E. Chicago Avenue, Chicago, IL 60611, USA

Peter Penzes: p-penzes@northwestern.edu

Abstract

Spine morphogenesis and plasticity are intimately linked to cognition, and there is strong evidence that aberrant regulation of spine plasticity is associated with physiological, behavioral, and pathological conditions. The neuronal guanine nucleotide exchange factor (GEF) kalirin is emerging as a key regulator of structural and functional plasticity at dendritic spines. Here, we review recent studies that have genetically and functionally linked kalirin signaling to a number of human disorders. Kalirin signaling may thus represent a disease mechanism and provide a novel therapeutic target.

Keywords

Mental disorder; DISC1; NRG1; erbB4; Glutamatergic; Postmortem; Genetic; Schizophrenia; Alzheimer's disease; ADHD; Addiction; Stroke

Introduction

Most excitatory synapses in the mammalian forebrain are located on dendritic spines. Actin dynamics can rapidly induce changes in spine morphology, which modulates synaptic properties and the potential for plasticity [1, 2]. During development, spine dynamics play a critical role in neural circuit formation. In mature neurons, synaptic activity drives spine dynamics, contributing to remodeling of neural circuits and experience-dependent plasticity [1, 2]. Several decades of research have documented changes in spine size and number associated with a number of physiological, behavioral, and pathological conditions. Importantly, circuit-level analysis indicates that relatively small changes in synapse strength or number may have a much greater effect on the overall function of circuits [3, 4].

Postmortem neuropathological studies using brain tissue from human patients have revealed that dendritic spine morphology and number are altered in a number of disorders of the central nervous system [5]. These alterations have been well characterized in intellectual disability, Down's syndrome [6], Rett syndrome [7], Fragile X syndrome [8], autism spectrum disorders (ASD) [9], schizophrenia [10, 11], and addiction [12–14]. Furthermore,

synaptic pathology has been associated with neurodegenerative disorders including Alzheimer's [15], Parkinson's [16], and Huntington's disease [17].

Spine morphogenesis is driven by actin remodeling and membrane trafficking events, which are controlled by small GTPase signaling [18]. Small GTPases function as molecular switches: in the active, GTP-bound state they promote actin remodeling and trafficking, and they become inactive by hydrolyzing GTP to GDP. Abnormal small GTPase signaling has been associated with several human pathologies. Signaling pathways involving Rac and Ras are particularly important since a large proportion of genes causing intellectual disability encode proteins in these small GTPase pathways [19, 20]. Importantly, the only anatomical alteration reported in non-syndromic mental retardation is abnormal spine morphology, intimately connecting small GTPase signaling, spine morphogenesis, and human cognition [19, 20]. GTPases are modulated by guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). GEFs and GAPs are complex, multidomain signaling proteins that may integrate multiple signals and have tissue- and cell-specific functions [1]. Among these, the Rac/Rho-GEF kalirin has been associated with a range of psychiatric and neurodegenerative disorders.

Kalirin is highly enriched in the forebrain and almost absent outside of the CNS; its most abundant isoform, kalirin-7, is localized to dendritic spines on cortical pyramidal neurons (Fig. 1a, b). Kalirin-7 plays a key role in structural and functional plasticity at excitatory synapses [21]. By activating Rac1 and its downstream effector, p21-activated kinase (PAK), kalirin facilitates actin remodeling [22, 23] such that overexpression of kalirin-7 leads to increased spine number, while knockdown leads to spine loss (Fig. 1c). Kalirin-7 has also been shown to mediate activity-dependent plasticity in dendritic spines. Xie and colleagues [24] found that NMDA receptor (NMDAR) activation-induced spine enlargement and increases in synaptic expression of AMPA receptors (AMPA receptors) were kalirin-7-dependent. Based on these well-characterized effects of kalirin on dendritic spines, it seems plausible that mutations or changes in expression of kalirin, or alterations in its upstream or downstream signaling partners, in human disorders would lead to aberrant dendritic spine number and morphology. Consistent with this, kalirin has been functionally and genetically implicated in the pathogenesis of several human disorders (see Table 1 for summary), most of which affect cognition and present with dendritic spine pathology. Here, we will discuss recent studies linking aberrant regulation of dendritic spine plasticity through altered kalirin signaling with several psychiatric and neurological disorders.

Kalirin and Schizophrenia

Schizophrenia is a psychiatric disorder that affects cognition and perception of reality that impacts 0.5–1% of the population. Symptoms emerge during late adolescence or early adulthood. The causes of this disease are not known and there are no effective treatments for the negative and cognitive symptoms. One of the most consistent neuropathological findings in postmortem studies of schizophrenic patients is reduced spine density in forebrain regions. Spine loss in the dorsolateral prefrontal cortex (DLPFC) [10] and auditory cortex have been observed in postmortem studies in schizophrenic patients [11]. Other studies have also reported reduced spine density in the subiculum and CA3 [25, 26]. Genetic and anatomical studies have linked a number of classical regulators of spine plasticity to schizophrenia; conversely, a number of schizophrenia susceptibility molecules have been shown to modulate spine morphology [5]. Such findings might shed light on the molecular mechanisms underlying spine pathology in schizophrenia. Among these molecules, several lines of evidence link altered kalirin signaling with schizophrenia.

In a postmortem study, kalirin mRNA expression was found to be reduced in the DLPFC of schizophrenia patients, irrespective of antipsychotic treatment [27]. Interestingly, kalirin loss correlated with spine loss on layer 3 PFC neurons [27]. A recent genome-wide association study (GWAS) in a Japanese population [28] detected association signals with schizophrenia at the region of the *KALRN* gene. Although single locus analysis did not reach genome-wide significance, the study confirmed a shared polygenic risk of schizophrenia between the Japanese and the Caucasian samples. An independent study also supported this association [29]. Following up on these findings, Kushima and colleagues [30] re-sequenced all exons of the *KALRN* gene and identified several rare missense mutations enriched in patients with schizophrenia as compared to non-psychiatric controls. A number of these sequence alterations are predicted to have functional and damaging consequences. The authors detected a significant association of the P2255T mutation (OR=2.09) as well as combined association of all mutations (OR=2.07) with schizophrenia. Interestingly, several of these mutations are in exons encoding protein domains present in kalirin-9 or -12 but not kalirin-7. Thus, multiple rare missense mutations in *KALRN* may contribute to genetic risk in schizophrenia.

Kalirin-Interacting Proteins and Schizophrenia

Recent studies also demonstrate that kalirin-7 physically and functionally interacts with several proteins previously implicated in schizophrenia. Kalirin-7 directly interacts with DISC1 (disrupted in schizophrenia) [31], a protein product of a leading schizophrenia susceptibility gene. Hayashi-Takagi and colleagues [32] have shown that DISC1 functions as a scaffold for kalirin-7 and modulates the access of kalirin-7 to Rac1, controlling the duration and intensity of Rac1 activation in response to NMDAR activation. In this context, DISC1 functions as a scaffold that augments the kalirin-7/PSD-95 interaction; kalirin's release from DISC1 enhances its GEF activity leading to the modulation of spine structure. Knockdown of DISC1 in cultured neurons for extended periods of time causes a reduction in spine area [32]. If schizophrenia-associated mutations disrupt DISC1's scaffolding function, they would be expected to have deleterious consequences on spine morphogenesis through altered kalirin signaling (Fig. 2).

Kalirin also interacts with and is modulated by the 5-HT_{2A} serotonin receptor (Fig. 2), a target of atypical antipsychotics which has also been genetically linked to schizophrenia [33]. Jones and colleagues [34] demonstrated that 5-HT_{2A} modulates spine morphogenesis in a kalirin-dependent manner. 5-HT_{2A} receptors colocalize with PSD-95 and kalirin-7 in spines of mature cortical neurons. Treatment of cultured neurons with the 5-HT_{2A} receptor agonist DOI rapidly induced an increase in spine size and PAK phosphorylation, and both of these effects were dependent on kalirin-7 targeting to the PSD [34]. Thus, 5-HT_{2A} and kalirin-7 are functionally linked, and 5-HT signaling may modulate kalirin-7 activity and synapse size at mature cortical synapses. Based on these studies, 5-HT receptors may act as upstream regulators of kalirin-7 signaling and thus may contribute a neuromodulatory element to kalirin-7 signal integration in spines.

Kalirin-7 also participates in a common pathway with neuregulin 1 (NRG1) and erbB4, two prominent schizophrenia susceptibility molecules, to regulate the morphology of interneuronal dendrites [35]. The tyrosine kinase erbB4 is thought to be the principal receptor for NRG1. Polymorphisms in NRG1 have been identified in patients with schizophrenia [36]. A rare copy number variant (CNV) for erbB4 has also been associated with schizophrenia; this mutation results in a protein lacking most of its intracellular kinase domain that has the effect of a dominant negative protein [37]. ErbB4 is highly expressed in interneurons and, to a lesser extent, in cortical pyramidal cells and dendritic spines [38]. This suggested that NRG1/erbB4/kalirin signaling may play a role in interneurons. Indeed,

while kalirin is robustly expressed in pyramidal neurons, it is also expressed in interneurons [39]. Interneuronal pathology is thought to play an important role in schizophrenia [40]. Ma and colleagues [41] demonstrated that endogenous kalirin-7 is localized to the postsynaptic side of excitatory synapses onto hippocampal interneurons. Consistent with this, Cahill and colleagues found that kalirin regulates interneuron dendritic growth downstream of NRG1 in mature cortical interneurons. Treatment of cortical interneurons with NRG1 increases dendritic length in a kalirin-dependent manner [35]. Conversely, cortical interneurons from erbB2/B4 conditional knockout mice have decreased dendritic length [35]. In cultured cortical interneurons, endogenous kalirin-7 colocalized with erbB4 and erbB4 co-immunoprecipitated with kalirin-7, indicating that kalirin-7 and erbB4 interact [35]. Kalirin may thus play a role in the normal development and function of inhibitory circuits, and its functional loss may contribute to the dysfunction of these circuits, in addition to excitatory circuits, in schizophrenia. NRG1 and erbB4 have been shown to affect spine morphology [38, 42], thus kalirin may also function downstream of these molecules in spines (Fig. 2).

P21-activated kinase (PAK) is a key regulator of actin remodeling, and a downstream effector of kalirin-7 and Rac1 [23]. Interestingly, missense mutations in PAK3 have been associated with psychotic disorders, primarily schizophrenia with premorbid mental retardation [43], and microdeletions that encompass PAK2 (3q29) have been found in schizophrenia patients [44]. These findings further implicate kalirin signaling in schizophrenia, as mutations in kalirin's downstream effectors are genetically associated with the disorder.

Taken together, these findings support a model whereby proteins associated with schizophrenia, NRG1, erbB4, DISC1, and 5-HT_{2a}, function in the same pathway with kalirin-7 and PAK to control spine morphogenesis (Fig. 2). These proteins might even form a “signalosome” [32], a multiprotein signaling complex in dendrites or spines. If the functional output of this pathway is the control of spine plasticity, alterations in any of the molecules in the pathway/complex might impair the output of the entire pathway, leading to spine pathology.

Kalirin Knockout Mice Have Disease-Relevant Phenotypes

Alterations in kalirin signaling may thus contribute to behavioral alterations relevant for schizophrenia. To test this, Cahill and colleagues generated a mouse line carrying a full knockout of KALRN [45]. Analysis of these mice revealed robustly reduced spine density in the cortex. Interestingly, KALRN KO mice have impaired working memory but do not show deficits in reference memory, indicating that kalirin may play a specific role in modulating working memory. Importantly, working memory deficits are a core endophenotype of schizophrenia. Recurrent excitation in prefrontal cortical microcircuits has been hypothesized to underlie working memory [46]. Reduced spine density on pyramidal neurons in such circuits, as it occurs in KALRN KO mice or human subjects with schizophrenia, may lead to gradual signal loss and diminished output of these circuits (Fig. 3). In addition to working memory deficits, KALRN KO mice exhibit other schizophrenia-related behavioral phenotypes such as impaired prepulse inhibition, decreased social interaction, and locomotor hyperactivity, which is reversed by the antipsychotic clozapine in KALRN heterozygote but not KO mice [45].

One unique feature of these mice is that the morphological and behavioral phenotypes emerge during adolescence, paralleling the onset of schizophrenia in humans, which also occurs during adolescence or young adulthood [47]. This particular feature might be useful in understanding the age dependence of schizophrenia emergence in humans. The molecular and cellular mechanisms underlying this delayed phenotype emergence are not known, and

warrant more investigation. One contributor could be “phenotype unmasking”, whereby natural changes in expression levels of similar proteins might uncover the effects of a genetic defect later in life. While multiple synaptic Rac1-GEFs (kalirin-7, Tiam1, β PIX) are present in both the hippocampus and cortex in young animals, the expression levels of Tiam1 and β PIX decrease significantly in the adult cortex, but not hippocampus [48]. Thus, by adulthood, kalirin-7 is the predominant synaptic Rac1-GEF in the cortex. Kalirin loss in the KALRN KO mouse, or reduced levels in humans, may thus lead to enhanced spine elimination or impaired activity-dependent stabilization in the cortex. Interestingly, prenatal knockdown of DISC1 also results in delayed onset circuit dysfunction [49], suggesting that the kalirin/DISC1 interaction may play a role in peri-adolescent spine stabilization. An important future direction for these studies is to characterize the development of spine morphological and behavioral phenotypes that correspond to presymptomatic and symptomatic stages of the disease.

Ma and colleagues generated another kalirin mutant mouse line, Kal7 KO, in which the exon unique to kalirin-7 has been deleted [50]. While kalirin-7 and Δ kalirin-7, a truncated isoform of kalirin-7 that is also expressed in the brain, are absent in the brains of Kal7 KO mice, kalirin-9 and kalirin-12 are upregulated by approximately 50% [50]. Contrary to the KALRN KO mice, Kal7 KO mice have significantly reduced spine size and density in the hippocampus [50]. As loss of the entire KALRN gene does not effect hippocampal spine density [45], upregulation of other kalirin isoforms may account for this, as both kalirin-9 and -12 (but not kalirin-7) contain RhoA GEF domains [51], which have been shown to play a role in spine elimination [52]. This suggests that compensatory upregulation of kalirin-9 or -12 in response to reduced kalirin-7 signaling might be a pathological mechanism in schizophrenia worth further investigation.

Kal7 KO mice have impaired contextual fear learning [50]. This learning deficit seems specific to fear associations, as Kal7 KO mice performed well in radial arm maze and novel object recognition tasks [50]. Consistent with this, in KALRN KO mice both context and cue-dependent fear conditioning are impaired, suggesting an amygdala deficit [53]. Both of these mouse models have deficits in contextual learning; however, the relevance of these deficits for schizophrenia is unclear. It seems plausible that behaviors in mouse models do not closely mimic behaviors observed in human disease because kalirin loss is global in the mouse, whereas it is likely cell population or region specific in humans. Both the KALRN KO and the Kal7 KO mice exhibit disease-relevant phenotypes and thus will be powerful tools for future investigation of mechanisms underlying synaptic plasticity and pathology.

Taken together, several lines of evidence support a role for kalirin in spine pathology in schizophrenia. Animal model studies suggest that these spine abnormalities might underlie specific behavioral alterations. Further studies in human subjects and model systems are needed to clarify whether kalirin alterations are a cause or consequence of spine pathology in schizophrenia, whether kalirin-mediated spine pathology is preferentially associated with specific disease diagnostic domains or phenotypes, and whether kalirin dysfunction is associated with specific subtypes of schizophrenia. In any case, therapeutically manipulating kalirin activity might provide an efficient way to reverse spine plasticity deficits in schizophrenia.

Kalirin and Alzheimer's Disease

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by loss of memory and other cognitive functions. AD affects 13% of Americans over the age of 65. Synapse and spine loss in the hippocampus and cortex are consistent postmortem findings in AD patients [54, 55]. Remarkably, synapse and dendrite loss are more robustly correlated with

cognitive decline than neurofibrillary tangles or neuronal loss [54]. Postmortem analysis has also indicated that synapse loss occurs in mild cognitive impairment and worsens in AD, suggesting that synapse loss precedes the onset of AD [56]. Compensatory synaptic changes may counteract the effects of synapse loss in AD [57]. A better understanding of the early stages of the disease and the compensatory mechanisms that are acting at this stage would profoundly impact the direction of future investigation of therapeutic interventions in AD.

Several recent studies implicate kalirin, along with its upstream regulators and downstream targets, in the pathology of AD (Fig. 4) [58]. Postmortem studies determined that kalirin mRNA and kalirin-7 protein are specifically and significantly reduced in the hippocampus of AD patients compared to controls [59, 60]. It is unknown whether kalirin loss plays a causal role in the pathogenesis of AD, but it is possible that these effects are secondary and occur in response to the presence of A β . Furthermore, it remains to be determined if kalirin loss leads to spine loss in AD, or if spine loss precedes kalirin loss.

EphB2 receptors are upstream regulators of kalirin signaling [23] that have been implicated in synaptic degeneration induced by A β . A β oligomers accumulate in the brain of AD patients and have been shown to cause synapse dysfunction and degeneration, as well as impairments in glutamatergic function [61]. Postmortem studies of AD patient brains and studies using hAPP transgenic mice have found that EphB2 receptors are reduced in the hippocampus in AD [62]. Furthermore, treating cultured hippocampal neurons with A β oligomers leads to decreased surface expression of NMDARs and EphB2 receptors [63]. In addition, EphB2 and A β oligomers may interact directly as they can be co-immunoprecipitated in a cell-free system as well as from primary neuron homogenates [64]. A critical downstream effector of EphB2 and kalirin-7 signaling, PAK, has also been associated with AD. Postmortem analysis of AD patient brains found that PAK protein and activation are markedly reduced and that phosphoPAK was mislocalized in the hippocampus of AD patients as well as in AD trans-genic mice [65].

Interestingly, kalirin-7 interacts with inducible nitric oxide synthase (iNOS) [66], which has been shown to be neurotoxic *in vitro* [67]. Kalirin inhibits iNOS activity by preventing formation of active homodimers in a heterologous system [66]. Postmortem studies found that iNOS activity was significantly increased in AD hippocampus [59]. Co-immunoprecipitation from human brain lysates confirmed that kalirin-7 and iNOS interact in the human brain [59]. Furthermore, overexpression of kalirin-7 in cultured cells reduces iNOS activity [59]. Thus, it has been hypothesized that reduced kalirin-7 expression in the hippocampus of AD patients could account for increased iNOS activity and possibly cell death [59].

Taken together, postmortem neuropathological and functional data suggest that the interactions of EphB and iNOS with kalirin-7 and its downstream effector PAK may be altered in AD, possibly due to the presence of A β oligomers at the synapse. Although there is no published genetic evidence implicating kalirin or any of the above proteins in the etiology of AD, current data support a potential role for these proteins in AD pathophysiology. Reduced function or loss of these proteins in spines could precipitate spine collapse, leading to synapse loss and cognitive decline (Fig. 4). Further studies in human subjects as well as in animal and cellular models are required to substantiate this hypothesis. If this proves to be the case, pharmacological enhancement of this pathway could provide a modality to delay or reverse synaptic pathology in AD, by fortifying synapses.

Kalirin and Other Disorders

Kalirin has been genetically and functionally associated with several other human disorders (Table 1). The KALRN gene has been genetically linked to adult ADHD. In a recent study,

Lesch and colleagues [68] identified 15 SNPs in the *KALRN* open reading frame that associated with ADHD. In the same study, SNPs associated with ADHD were also identified in *CDH13*, the gene encoding cadherin 13 and *CTNNA2*, the gene encoding α N-catenin [68]. Cadherins have been shown to regulate spine morphology in a kalirin-dependent manner, thus aberrant function of one or both of these proteins may have detrimental effects on spine remodeling [69].

Huntington's disease (HD) is a genetic neurodegenerative disorder that is caused by expanded trinucleotide repeats in the widely expressed huntingtin protein [70, 71]. Huntingtin-associated protein 1 (HAP1) is one of only a few known proteins that interact with huntingtin in a repeat length-dependent manner [72]. Kalirin has been shown to interact with HAP1 [73]. While this interaction requires further examination, it is of interest as it may provide insight into the functional significance of the interaction between huntingtin and HAP1, and also suggests a potential role for Rac signaling in HD.

Recent studies have also identified kalirin as a key factor in a mouse model of addiction. It has been suggested that drug addiction is the result of aberrant learning mechanisms, which could be explained by aberrant regulation of plasticity at dendritic spines [74]. Since kalirin has a key role in regulation of structural and functional plasticity at dendritic spines, it is possible that kalirin may play a role in addiction. Kiraly and colleagues used Kal7 KO mice to demonstrate that kalirin-7 is required for normal morphological and behavioral responses to chronic cocaine administration [75]. In wild-type mice, chronic cocaine treatment induced an increase in kalirin-7 protein and mRNA in the nucleus accumbens (NAc) as well as an increase in dendritic spine density and size in the NAc. Interestingly, chronic cocaine treatment in Kal7 KO mice did not alter spine density and induced a decrease in spine size. Moreover, Kal7 KO mice showed increased locomotor sensitization to cocaine following chronic treatment and maintained this higher sensitization for at least 1 week following the last dose of cocaine. In addition, Kal7 KO mice showed significantly diminished conditioned place preference for cocaine. Importantly, Kal7 KO mice showed no difference from wild-type mice in place preference for food, indicating a cocaine-specific deficit in place conditioning. Furthermore, chronic treatment with cocaine has been shown to alter the expression profile of specific kalirin isoforms by altering usage of isoform-specific promoters. Chronic cocaine exposure increases the usage of the promoter and the 3' exon that are specific to kalirin-7 and Δ -kalirin-7, while usage of the kalirin-9 specific 3' exon was reduced [76].

Kalirin signaling may also be involved in depression and chronic stress. Chronic restraint stress (CRS) causes a depression-like behavioral and physiological response in mice, including decreased time to immobility on a forced-swim test and reduced body weight [77]. Interestingly, recent studies have demonstrated that kalirin-7 expression is significantly reduced in the mouse hippocampus following CRS [77]. Furthermore, administration of estrogen during CRS attenuated the behavioral and physiological responses and increased kalirin-7 expression [77].

Genetic studies have identified *KALRN* as a risk factor for coronary artery disease [78, 79]. Based on this genetic evidence and the fact that kalirin has been implicated in nitric oxide (NOS) signaling, recent genetic studies have sought to determine if *KALRN* is genetically linked to ischemic stroke. In a case-control study, Krug and colleagues identified two SNPs in the 5' region of *KALRN* and one in the *ROPNI-KALRN* intergenic region that is associated with increased risk for ischemic stroke [80]. However, the link between SNPs in the *KALRN* gene and risk for ischemic stroke requires further validation, as another study was unable to replicate the linkage of all three SNPs in two of the three sample populations used [81]. In addition, a recent study has characterized changes in kalirin-7 protein

expression after ischemic stroke in the gerbil hippocampus. Beresewicz and colleagues [82] found that under control conditions, kalirin-7 levels were significantly higher in the ischemia-resistant CA2/3 and DG regions than in the ischemia-vulnerable CA1 region of the hippocampus. Interestingly, after 5 min of ischemia and 1 h of reperfusion, kalirin-7 was significantly reduced in CA2/3 and DG and was significantly elevated in CA1. In another study, Jourdain and colleagues [83] observed cytoskeletal rearrangements in organotypic hippocampal cultures following oxygen and glucose deprivation, these were found to be Ca^{2+} - and NMDAR-dependent. Thus, changes in kalirin-7 levels may act downstream of NMDARs in ischemia to induce cytoskeletal rearrangements.

In sum, accumulating evidence implicates kalirin dysfunction in a broad range of neurological and psychiatric disorders, in addition to schizophrenia and AD. As all of these disorders are associated with abnormal spine plasticity and neuronal connectivity, kalirin may be part of the disease pathway and may provide a therapeutic target for reversing these deficits.

Conclusions and Future Directions

Genetic, morphological, and functional studies suggest that kalirin might be a common mediator of synaptic pathology in several psychiatric and neurological disorders. The strongest evidence to date links kalirin to schizophrenia, but there is mounting evidence that also suggests possible roles in AD, addiction, chronic stress, stroke, and Huntington's. This is consistent with the fact that kalirin functions in common pathways with molecules previously associated with these disorders to regulate normal spine formation, maintenance, and plasticity. Kalirin-mediated spine pathology might thus be a cellular phenotype of interest in these disorders. It may be possible to rescue abnormal spine plasticity, and thus the associated behavioral deficits, by altering kalirin activity or function. Further studies, preferably in human subjects, are needed to strengthen these conclusions.

Acknowledgments

We thank Kelly Jones, Mike Cahill, Jon Van-Leeuwen, and Zhong Xie for their useful input. This work was supported by a grant from NIH-NIMH to P.P. (R01MH071316).

References

1. Carlisle HJ, Kennedy MB. Spine architecture and synaptic plasticity. *Trends Neurosci.* 2005; 28:182–187. [PubMed: 15808352]
2. Alvarez VA, Sabatini BL. Anatomical and physiological plasticity of dendritic spines. *Annu Rev Neurosci.* 2007; 30:79–97. [PubMed: 17280523]
3. Chklovskii DB, Mel BW, Svoboda K. Cortical rewiring and information storage. *Nature.* 2004; 431:782–788. [PubMed: 15483599]
4. Chen JL, Nedivi E. Neuronal structural remodeling: is it all about access? *Curr Opin Neurobiol.* 2010; 20:557–562. [PubMed: 20621466]
5. Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. *Nat Neurosci.* 2011; 14:285–293. [PubMed: 21346746]
6. Kaufmann WE, Moser HW. Dendritic anomalies in disorders associated with mental retardation. *Cereb Cortex.* 2000; 10:981–991. [PubMed: 11007549]
7. Zhou Z, Hong EJ, Cohen S, Zhao WN, Ho HY, Schmidt L, Chen WG, Lin Y, Savner E, Griffith EC, Hu L, Steen JA, Weitz CJ, Greenberg ME. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. *Neuron.* 2006; 52:255–269. [PubMed: 17046689]
8. Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. *Nat Rev Neurosci.* 2005; 6:376–387. [PubMed: 15861180]

9. Hutsler JJ, Zhang H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. *Brain Res.* 2010; 1309:83–94. [PubMed: 19896929]
10. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. *Arch Gen Psychiatry.* 2000; 57:65–73. [PubMed: 10632234]
11. Sweet RA, Hentel RA, Zhang W, Sampson AR, Lewis DA. Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. *Neuropsychopharmacology.* 2009; 34:374–389. [PubMed: 18463626]
12. Robinson TE, Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. *J Neurosci.* 1997; 17:8491–8497. [PubMed: 9334421]
13. Robinson TE, Kolb B. Structural plasticity associated with exposure to drugs of abuse. *Neuropharmacology.* 2004; 47(Suppl 1):33–46. [PubMed: 15464124]
14. Zhou FC, Anthony B, Dunn KW, Lindquist WB, Xu ZC, Deng P. Chronic alcohol drinking alters neuronal dendritic spines in the brain reward center nucleus accumbens. *Brain Res.* 2007; 1134:148–161. [PubMed: 17198693]
15. Knobloch M, Mansuy IM. Dendritic spine loss and synaptic alterations in alzheimer's disease. *Mol Neurobiol.* 2008; 37:73–82. [PubMed: 18438727]
16. Day M, Wang Z, Ding J, An X, Ingham CA, Shering AF, Wokosin D, Ilijic E, Sun Z, Sampson AR, Mugnaini E, Deutch AY, Sesack SR, Arbuthnott GW, Surmeier DJ. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. *Nat Neurosci.* 2006; 9:251–259. [PubMed: 16415865]
17. Spires TL, Grote HE, Garry S, Cordery PM, Van Dellen A, Blakemore C, Hannan AJ. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Hun-tington's disease transgenic mice. *Eur J Neurosci.* 2004; 19:2799–2807. [PubMed: 15147313]
18. Tolias KF, Duman JG, Um K. Control of synapse development and plasticity by Rho GTPase regulatory proteins. *Prog Neurobiol.* 2011; 94:133–148. [PubMed: 21530608]
19. Ramakers GJ. Rho proteins, mental retardation and the cellular basis of cognition. *Trends Neurosci.* 2002; 25:191–199. [PubMed: 11998687]
20. Newey SE, Velamoor V, Govek EE, Van Aelst L. Rho GTPases, dendritic structure, and mental retardation. *J Neurobiol.* 2005; 64:58–74. [PubMed: 15884002]
21. Penzes P, Jones KA. Dendritic spine dynamics—a key role for kalirin-7. *Trends Neurosci.* 2008; 31:419–427. [PubMed: 18597863]
22. Penzes P, Johnson RC, Sattler R, Zhang X, Hugarir RL, Kambam-pati V, Mains RE, Eipper BA. The neuronal Rho-GEF Kalirin-7 interacts with PDZ domain-containing proteins and regulates dendritic morphogenesis. *Neuron.* 2001; 29:229–242. [PubMed: 11182094]
23. Penzes P, Beeser A, Chernoff J, Schiller MR, Eipper BA, Mains RE, Hugarir RL. Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rho-GEF kalirin. *Neuron.* 2003; 37:263–274. [PubMed: 12546821]
24. Xie Z, Srivastava DP, Photowala H, Kai L, Cahill ME, Woolfrey KM, Shum CY, Surmeier DJ, Penzes P. Kalirin-7 controls activity-dependent structural and functional plasticity of dendritic spines. *Neuron.* 2007; 56:640–656. [PubMed: 18031682]
25. Kolomeets NS, Orlovskaya DD, Rachmanova VI, Uranova NA. Ultrastructural alterations in hippocampal mossy fiber synapses in schizophrenia: a postmortem morphometric study. *Synapse.* 2005; 57:47–55. [PubMed: 15858835]
26. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. *Br J Psychiatry.* 2006; 188:510–518. [PubMed: 16738340]
27. Hill JJ, Hashimoto T, Lewis DA. Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia. *Mol Psychiatry.* 2006; 11:557–566. [PubMed: 16402129]
28. Ikeda M, et al. Genome-wide association study of schizophrenia in a Japanese population. *Biol Psychiatry.* 2011; 69:472–478. [PubMed: 20832056]
29. St Jean, PL. [Accessed 8 August 2010] Genes associated with schizophrenia identified using a whole genome scan. 2008. <http://www.freepatentsonline.com/y2008/0176240.html>

30. Kushima I, Nakamura Y, Aleksic B, Ikeda M, Ito Y, Shiino T, Okochi T, Fukuo Y, Ujike H, Suzuki M, Inada T, Hashimoto R, Takeda M, Kaibuchi K, Iwata N, Ozaki N. Resequencing and association analysis of the KALRN and EPHB1 genes and their contribution to schizophrenia susceptibility. *Schizophr Bull.* 2010 Epub ahead of print.
31. Millar JK, Christie S, Porteous DJ. Yeast two-hybrid screens implicate DISC1 in brain development and function. *Biochem Biophys Res Commun.* 2003; 311:1019–1025. [PubMed: 14623284]
32. Hayashi-Takagi A, Takaki M, Graziane N, Seshadri S, Murdoch H, Dunlop AJ, Makino Y, Seshadri AJ, Ishizuka K, Srivastava DP, Xie Z, Baraban JM, Houslay MD, Tomoda T, Brandon NJ, Kamiya A, Yan Z, Penzes P, Sawa A. Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. *Nat Neurosci.* 2010; 13:327–332. [PubMed: 20139976]
33. Golimbet VE, Lavrushina OM, Kaleda VG, Abramova LI, Lezheiko TV. Supportive evidence for the association between the T102C 5-HT2A gene polymorphism and schizophrenia: a large-scale case–control and family-based study. *Eur Psychiatry.* 2007; 22:167–170. [PubMed: 17240119]
34. Jones KA, Srivastava DP, Allen JA, Strachan RT, Roth BL, Penzes P. Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. *Proc Natl Acad Sci USA.* 2009; 106:19575–19580. [PubMed: 19889983]
35. Cahill ME, Jones KA, Rafalovich I, Xie Z, Barros CS, Muller U, Penzes P. Control of interneuron dendritic growth through NRG1/erbB4-mediated kalirin-7 disinhibition. *Mol Psychiatry.* 2011 Epub ahead of print.
36. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. *Nat Rev Neurosci.* 2008; 9:437–452. [PubMed: 18478032]
37. Walsh T, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science.* 2008; 320:539–543. [PubMed: 18369103]
38. Barros CS, Calabrese B, Chamero P, Roberts AJ, Korzus E, Lloyd K, Stowers L, Mayford M, Halpain S, Muller U. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. *Proc Natl Acad Sci USA.* 2009; 106:4507–4512. [PubMed: 19240213]
39. Ma XM, Johnson RC, Mains RE, Eipper BA. Expression of kalirin, a neuronal GDP/GTP exchange factor of the trio family, in the central nervous system of the adult rat. *J Comp Neurol.* 2001; 429:388–402. [PubMed: 11116227]
40. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. *Nat Rev Neurosci.* 2005; 6:312–324. [PubMed: 15803162]
41. Ma XM, Wang Y, Ferraro F, Mains RE, Eipper BA. Kalirin-7 is an essential component of both shaft and spine excitatory synapses in hippocampal interneurons. *J Neurosci.* 2008; 28:711–724. [PubMed: 18199770]
42. Li B, Woo RS, Mei L, Malinow R. The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. *Neuron.* 2007; 54:583–597. [PubMed: 17521571]
43. Morrow EM, Kane A, Goff DC, Walsh CA. Sequence analysis of P21-activated kinase 3 (PAK3) in chronic schizophrenia with cognitive impairment. *Schizophr Res.* 2008; 106:265–267. [PubMed: 18805672]
44. Mulle JG, Dodd AF, McGrath JA, Wolyniec PS, Mitchell AA, Shetty AC, Sobreira NL, Valle D, Rudd MK, Satten G, Cutler DJ, Pulver AE, Warren ST. Microdeletions of 3q29 confer high risk for schizophrenia. *Am J Hum Genet.* 2010; 87:229–236. [PubMed: 20691406]
45. Cahill ME, Xie Z, Day M, Photowala H, Barbolina MV, Miller CA, Weiss C, Radulovic J, Sweatt JD, Disterhoft JF, Surmeier DJ, Penzes P. Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes. *Proc Natl Acad Sci USA.* 2009; 106:13058–13063. [PubMed: 19625617]
46. Durstewitz D, Seamans JK, Sejnowski TJ. Neurocomputational models of working memory. *Nat Neurosci.* 2000; 3(Suppl):1184–1191. [PubMed: 11127836]
47. Lewis DA, Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. *Neuropsychopharmacology.* 2008; 33:141–165. [PubMed: 17805309]
48. Penzes P, Cahill ME, Jones KA, Srivastava DP. Convergent CaMK and RacGEF signals control dendritic structure and function. *Trends Cell Biol.* 2008; 18:405–413. [PubMed: 18701290]

49. Niwa M, Kamiya A, Murai R, Kubo K, Gruber AJ, Tomita K, Lu L, Tomisato S, Jaaro-Peled H, Seshadri S, Hiyama H, Huang B, Kohda K, Noda Y, O'Donnell P, Nakajima K, Sawa A, Nabeshima T. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. *Neuron*. 2010; 65:480–489. [PubMed: 20188653]
50. Ma XM, Kiraly DD, Gaier ED, Wang Y, Kim EJ, Levine ES, Eipper BA, Mains RE. Kalirin-7 is required for synaptic structure and function. *J Neurosci*. 2008; 28:12368–12382. [PubMed: 19020030]
51. Rabiner CA, Mains RE, Eipper BA. Kalirin: a dual Rho guanine nucleotide exchange factor that is so much more than the sum of its many parts. *Neuroscientist*. 2005; 11:148–160. [PubMed: 15746383]
52. Tashiro A, Minden A, Yuste R. Regulation of dendritic spine morphology by the rho family of small GTPases: antagonistic roles of Rac and Rho. *Cereb Cortex*. 2000; 10:927–938. [PubMed: 11007543]
53. Xie Z, Cahill ME, Radulovic J, Wang J, Campbell SL, Miller CA, Sweatt JD, Penzes P. Hippocampal phenotypes in kalirin-deficient mice. *Mol Cell Neurosci*. 2011; 46:45–54. [PubMed: 20708080]
54. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. *Ann Neurol*. 1990; 27:457–464. [PubMed: 2360787]
55. Selkoe DJ. Alzheimer's disease is a synaptic failure. *Science*. 2002; 298:789–791. [PubMed: 12399581]
56. Arendt T. Synaptic degeneration in Alzheimer's disease. *Acta Neuropathol*. 2009; 118:167–179. [PubMed: 19390859]
57. Fiala JC, Spacek J, Harris KM. Dendritic spine pathology: cause or consequence of neurological disorders? *Brain Res Brain Res Rev*. 2002; 39:29–54. [PubMed: 12086707]
58. Penzes P, Vanleeuwen JE. Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease. *Brain Res Rev*. 2011; 67:184–192. [PubMed: 21276817]
59. Youn H, Ji I, Ji HP, Markesbery WR, Ji TH. Under-expression of Kalirin-7 Increases iNOS activity in cultured cells and correlates to elevated iNOS activity in Alzheimer's disease hippocampus. *J Alzheimers Dis*. 2007; 12:271–281. [PubMed: 18057561]
60. Youn H, Jeoung M, Koo Y, Ji H, Markesbery WR, Ji I, Ji TH. Kalirin is under-expressed in Alzheimer's disease hippocampus. *J Alzheimers Dis*. 2007; 11:385–397. [PubMed: 17851188]
61. Viola KL, Velasco PT, Klein WL. Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). *J Nutr Health Aging*. 2008; 12:51S–57S. [PubMed: 18165846]
62. Simon AM, de Maturana RL, Ricobaraza A, Escribano L, Schiapparelli L, Cuadrado-Tejedor M, Perez-Mediavilla A, Avila J, Del Rio J, Frechilla D. Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. *J Alzheimers Dis*. 2009; 17:773–786. [PubMed: 19542617]
63. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. *J Neurosci*. 2007; 27:796–807. [PubMed: 17251419]
64. Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K, Yu GQ, Mucke L. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. *Nature*. 2011; 469:47–52. [PubMed: 21113149]
65. Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE, Weisbart RH, Teter B, Frautschy SA, Cole GM. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. *Nat Neurosci*. 2006; 9:234–242. [PubMed: 16415866]
66. Ratovitski EA, Alam MR, Quick RA, McMillan A, Bao C, Kozlovsky C, Hand TA, Johnson RC, Mains RE, Eipper BA, Lowenstein CJ. Kalirin inhibition of inducible nitric-oxide synthase. *J Biol Chem*. 1999; 274:993–999. [PubMed: 9873042]

67. Mitrovic B, Ignarro LJ, Vinters HV, Akers MA, Schmid I, Uittenbo-gaart C, Merrill JE. Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes. *Neuroscience*. 1995; 65:531–539. [PubMed: 7777166]
68. Lesch KP, Timmesfeld N, Renner TJ, Halperin R, Roser C, Nguyen TT, Craig DW, Romanos J, Heine M, Meyer J, Freitag C, Warnke A, Romanos M, Schafer H, Walitza S, Reif A, Stephan DA, Jacob C. Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. *J Neural Transm*. 2008; 115:1573–1585. [PubMed: 18839057]
69. Xie Z, Photowala H, Cahill ME, Srivastava DP, Woolfrey KM, Shum CY, Haganir RL, Penzes P. Coordination of synaptic adhesion with dendritic spine remodeling by AF-6 and kalirin-7. *J Neurosci*. 2008; 28:6079–6091. [PubMed: 18550750]
70. Group THsDCR. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell*. 1993; 72:971–983. [PubMed: 8458085]
71. Li SH, Schilling G, Young WS 3rd, Li XJ, Margolis RL, Stine OC, Wagster MV, Abbott MH, Franz ML, Ranen NG, et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. *Neuron*. 1993; 11:985–993. [PubMed: 8240819]
72. Li XJ, Li SH, Sharp AH, Nucifora FC Jr, Schilling G, Lanahan A, Worley P, Snyder SH, Ross CA. A huntingtin-associated protein enriched in brain with implications for pathology. *Nature*. 1995; 378:398–402. [PubMed: 7477378]
73. Colomer V, Engelender S, Sharp AH, Duan K, Cooper JK, Lanahan A, Lyford G, Worley P, Ross CA. Huntingtin-associated protein 1 (HAP1) binds to a Trio-like polypeptide, with a rac1 guanine nucleotide exchange factor domain. *Hum Mol Genet*. 1997; 6:1519–1525. [PubMed: 9285789]
74. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. *Annu Rev Neurosci*. 2006; 29:565–598. [PubMed: 16776597]
75. Kiraly DD, Ma XM, Mazzone CM, Xin X, Mains RE, Eipper BA. Behavioral and morphological responses to cocaine require kalirin7. *Biol Psychiatry*. 2010; 68:249–255. [PubMed: 20452575]
76. Mains RE, Kiraly DD, Eipper-Mains JE, Ma XM, Eipper BA. Kalrn promoter usage and isoform expression respond to chronic cocaine exposure. *BMC Neurosci*. 2011; 12:20. [PubMed: 21329509]
77. Li W, Li QJ, An SC. Preventive effect of estrogen on depression-like behavior induced by chronic restraint stress. *Neurosci Bull*. 2010; 26:140–146.
78. Wang L, Hauser ER, Shah SH, Pericak-Vance MA, Haynes C, Crosslin D, Harris M, Nelson S, Hale AB, Granger CB, Haines JL, Jones CJ, Crossman D, Seo D, Gregory SG, Kraus WE, Goldschmidt-Clermont PJ, Vance JM. Peakwide mapping on chromosome 3q13 identifies the kalirin gene as a novel candidate gene for coronary artery disease. *Am J Hum Genet*. 2007; 80:650–663. [PubMed: 17357071]
79. Ikram MA, et al. Genomewide association studies of stroke. *N Engl J Med*. 2009; 360:1718–1728. [PubMed: 19369658]
80. Krug T, et al. Kalirin: a novel genetic risk factor for ischemic stroke. *Hum Genet*. 2010; 127:513–523. [PubMed: 20107840]
81. Olsson S, Jood K, Melander O, Sjogren M, Norrving B, Nilsson M, Lindgren A, Jern C. Lack of association between genetic variations in the KALRN region and ischemic stroke. *Clin Biochem*. 2011; 44:1018–1020. [PubMed: 21664346]
82. Beresewicz M, Kowalczyk JE, Zablocka B. Kalirin-7, a protein enriched in postsynaptic density, is involved in ischemic signal transduction. *Neurochem Res*. 2008; 33:1789–1794. [PubMed: 18338255]
83. Jourdain P, Nikonenko I, Alberi S, Muller D. Remodeling of hippocampal synaptic networks by a brief anoxia-hypoglycemia. *J Neurosci*. 2002; 22:3108–3116. [PubMed: 11943814]

Fig. 1. Kalirin-7 is localized to dendritic spines and modulates dendritic spine morphogenesis. **a** This schematic of kalirin-7 domains shows the N-terminal Sec14p domain, followed by nine spectrin-like repeats. The Dbl homology (*DH*) and pleckstrin homology (*PH*) domains confer kalirin's GEF activity, and kalirin-7 has a C-terminal PDZ-binding domain. **b** Kalirin-7 is localized to dendritic spines of cortical pyramidal neurons. **c** Kalirin-7 regulates dendritic spine dynamics in cortical pyramidal neurons. Overexpression of kalirin-7 increases spine size and number, while RNAi-mediated knockdown reduces spine size and number

Fig. 2.

Kalirin-7 interacts with schizophrenia-associated proteins. This model shows kalirin signaling and interactions under non-pathological conditions. Activation of postsynaptic NMDARs leads to dissociation of the PSD-95/DISC1/kalirin-7 complex, thus allowing kalirin-7 to activate its downstream target, Rac1. Activation of postsynaptic NMDARs also increases trafficking of AMPARs to the post-synaptic density. NRG1 activates post-synaptic erbB4 receptors which regulate kalirin-7. 5-HT_{2A} receptor activation modulates dendritic spine density in a kalirin-dependent manner. Kalirin-7 activates Rac1 by exchanging GDP for GTP. Rac1 in turn activates PAK, which then initiates actin remodeling. Proteins outlined in bold have been genetically associated with schizophrenia (kalirin-7, DISC1, erbB4, NRG1, 5-HT_{2A}, PAK2, and PAK3)

Fig. 3.
The effects of spine loss on recurrent excitation in neocortical circuits. Reduced spine numbers may diminish signal output in recurrent cortical networks, and thus impair working memory

Fig. 4. Kalirin-7 interacts with Alzheimer's disease-associated proteins. Amyloid β oligomers cause a decrease in surface expression of NMDARs and EphB2 receptors in AD, which likely leads to decreased kalirin and PAK signaling, leading to synapse loss and cognitive impairment. Proteins associated with AD are outlined in *bold* ($A\beta$ oligomers and kalirin-7)

Table 1

Summary of evidence for kalirin association with disease

Disease	Genetic association	Postmortem evidence	Molecular association	Animal models	References
Schizophrenia	GWAS, rare missense mutations	↓ mRNA	DISC1, ErbB4, NRG1, 5-HT _{2A} , NMDAR, PSD-95	KALRN KO, Kal7 KO	[23, 27, 32, 34, 35, 41, 45, 50]
Alzheimer's disease	–	↓ mRNA ↓ protein	iNOS, PAK, EphB2	–	[59, 60, 66]
ADHD	GWAS	–	–	–	[68]
Addiction	–	–	–	Kal7 KO, addiction in mouse model	[75, 76]
Huntington's disease	–	–	HAP1	–	[73]
Stress	–	–	–	Chronic restraint stress in mice	[77]
Ischemic stroke	Case-control	–	–	Induced ischemia in mice	[80, 82]
Coronary artery disease	GWAS, association linkage	–	–	–	[78, 79]